Want to see FOCL full AI Analyst Report?
FOCL Stock Chart & Stats
$4.39
$0.11(1.82%)
At close: 4:00 PM EDT
$4.39
$0.11(1.82%)
Day’s Range― - ―
52-Week Range$1.75 - $6.40
Previous CloseN/A
Volume46.33K
Average Volume (3M)164.35K
Market Cap
$156.30M
Enterprise Value$214.53
Total Cash (Recent Filing)$21.54M
Total Debt (Recent Filing)$39.89M
Price to Earnings (P/E)―
Beta1.10
Next Earnings
Nov 05, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.04
Shares Outstanding37,527,950
10 Day Avg. Volume96,953
30 Day Avg. Volume164,348
Financial Highlights & Ratios
PEG Ratio-0.10
Price to Book (P/B)6.35
Price to Sales (P/S)1.74
P/FCF Ratio-5.76
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$9.75Price Target Upside122.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.95
Revenue Forecast (FY)$58.00M
Bulls Say, Bears Say
Bulls Say
HIFU Growth And Installed BaseStrong system sales and a larger installed base expand market reach and create a foundation for recurring consumables, service revenue and procedure growth over the next several quarters.
Procedure Utilization And Margin ExpansionHigher utilization supports recurring revenue from consumables and services, while improved gross margin indicates potential operating leverage from lower system costs, pricing and scale.
Reimbursement And Indication ExpansionImproving reimbursement can strengthen hospital economics, while additional indications broaden the addressable market and diversify long-term growth beyond prostate cancer treatment.
Bears Say
Persistent Losses And Revenue ContractionSustained operating and net losses despite relatively stable revenue indicate that commercialization costs remain too high, limiting internal funding capacity and delaying a durable path to profitability.
Weak Balance Sheet And Funding DependenceNegative equity, rising debt and continued cash burn reduce financial flexibility. The completed equity raise improves liquidity, but ongoing reliance on external capital remains a structural risk.
High Costs And Early-Stage DiversificationElevated spending can prolong losses before new indications contribute meaningfully. Execution, regulatory and adoption risks therefore remain significant while the company funds commercial expansion and R&D.
FocalTherics News
FOCL FAQ
What was FocalTherics’s price range in the past 12 months?
FocalTherics lowest stock price was $1.75 and its highest was $6.40 in the past 12 months.
What is FocalTherics’s market cap?
FocalTherics’s market cap is $156.30M.
When is FocalTherics’s upcoming earnings report date?
FocalTherics’s upcoming earnings report date is Nov 05, 2026 which is in 61 days.
How were FocalTherics’s earnings last quarter?
FocalTherics released its earnings results on Aug 13, 2026. The company reported -$0.39 earnings per share for the quarter, missing the consensus estimate of -$0.215 by -$0.175.
Is FocalTherics overvalued?
According to Wall Street analysts FocalTherics’s price is currently Undervalued.
Does FocalTherics pay dividends?
FocalTherics does not currently pay dividends.
What is FocalTherics’s EPS estimate?
FocalTherics’s EPS estimate is -0.22.
How many shares outstanding does FocalTherics have?
FocalTherics has 37,527,950 shares outstanding.
What happened to FocalTherics’s price movement after its last earnings report?
FocalTherics reported an EPS of -$0.39 in its last earnings report, missing expectations of -$0.215. Following the earnings report the stock price went up 2.808%.
Which hedge fund is a major shareholder of FocalTherics?
Currently, no hedge funds are holding shares in FOCL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
FocalTherics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.75 (122.10% Upside)
$9.75 (122.10% Upside)
Blogger Sentiment
Bullish
FOCL Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $551.0K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
64.68%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-7.08%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
FocalTherics
EDAP TMS S.A. operates as a holding company, with its subsidiary primarily focused on the innovation, manufacturing, and distribution of advanced, minimally invasive medical devices engineered to address urological conditions. The company's activities are organized into two principal divisions: High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS). The HIFU segment is dedicated to the creation, production, and commercialization of devices that employ HIFU technology for the precise, non-surgical elimination of certain localized tumors. In contrast, the UDS division concentrates on the entire lifecycle—from development and marketing to manufacturing and servicing—of medical instruments used for the minimally invasive diagnosis and treatment of various urological disorders, particularly urinary stones and other related clinical indications. This enterprise was founded on December 3, 1979, and its corporate headquarters are located in Vaulx-en-Velin, France.
FOCL Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed clear commercial momentum: double-digit revenue growth (39% YoY), record capital system sales, strong procedure volume growth (47% YoY), margin improvement to 55.6%, meaningful regulatory/reimbursement progress, and a near-term $40M equity raise to fund commercial expansion and R&D. Offsetting these positives are rising operating expenses, a sizable noncash warrant charge ($6.3M) that pushed shareholder equity negative ($-3.2M), reliance on the pending equity raise to strengthen the balance sheet, and a 34% decline in discontinued operations revenue. On balance, the business shows accelerating revenue, improving margins and strategic progress that outweigh the financial and accounting headwinds, with the upcoming equity close expected to materially improve capitalization.View all FOCL earnings summariesFOCL Stock 12 Month Forecast
Average Price Target
$9.75
▲(122.10% Upside)
Technical Analysis
Ownership Overview
6.34% Insiders
1.17% Mutual Funds
28.88% Other Institutional Investors
63.62% Public Companies and
Individual Investors